📌 Key Takeaways
- A SCALE Music City 2026 survey of 406 healthcare professionals found that 91% believe lean muscle loss contributes moderately or significantly to skin laxity after GLP-1-related weight loss.
- GLP-1 drugs like semaglutide (Ozempic/Wegovy) suppress appetite so aggressively that the body catabolizes both fat and muscle—removing the structural scaffold beneath the skin.
- The emerging 2026 paradigm shifts from “replenish” to “protect and strengthen”:
integrating EMS devices, resistance training, and protein optimization alongside aesthetic procedures. - Experts now recommend designing an aesthetic plan before starting GLP-1 therapy—not after the damage is visible.
For years, the standard answer to post-weight-loss facial aging was straightforward:
fat disappears → volume drops → fill it back with hyaluronic acid or a facelift.
That logic was never wrong.
But a large-scale survey presented at SCALE Music City 2026 in Nashville, Tennessee, suggests it may be dangerously incomplete.
The survey’s headline finding:
“The primary accelerant of facial sagging after GLP-1 weight loss may not be fat loss at all—it may be the loss of lean muscle mass.”
That single insight is forcing a fundamental rethink of how aesthetic medicine approaches patients on Ozempic, Wegovy, Mounjaro, and other GLP-1 receptor agonists.
INDEX
What SCALE 2026 Actually Found
The survey, conducted by Franco J et al. and presented at SCALE Music City (May 13–17, 2026),
gathered responses from 406 healthcare professionals actively treating GLP-1 patients.
The conventional understanding of “Ozempic Face” looked like this:
Rapid weight loss → facial fat pads dissolve → cheeks hollow and sag → restore with fillers or fat grafting.
That model isn’t obsolete.
But the SCALE 2026 data adds a second, equally important variable.
Source: Franco J et al. SCALE Music City, May 13–17, 2026. EMJ Reviews, May 18, 2026.
Note: This is a clinician perception survey, not a randomized controlled trial.
Results reflect clinical impressions, not confirmed causal mechanisms.
Nine out of ten clinicians treating GLP-1 patients now believe
that muscle loss—not just fat loss—is a primary driver of the sagging and hollowing
that patients describe as “looking older overnight.”
This doesn’t replace the fat-loss explanation.
It adds a structural layer that the old model missed entirely:
“Fat disappeared → volume is gone. Muscle disappeared → the entire scaffold is gone.”
Why GLP-1 Drugs Deplete Muscle Mass
GLP-1 receptor agonists work by suppressing appetite and slowing gastric emptying.
The result is a dramatic reduction in caloric intake—often more aggressive than patients or clinicians anticipate.
When caloric deficit is severe, the body doesn’t burn fat exclusively.
It catabolizes lean tissue—including skeletal muscle—to meet energy demands.
Total fat mass decreased approximately 18% over 12 months.
Lean body mass declined by approximately 3 kg in the first 7 months, then stabilized.
Grip strength improved and sarcopenic obesity rates declined—suggesting functional muscle strength may be partially preserved.
However, the structural volume loss in facial musculature remains a separate clinical concern.
Three mechanisms compound the problem for the face specifically:
- Facial muscles (mimetic muscles) lose volume,
synergistically accelerating the hollowing caused by fat pad loss. - Muscle provides the structural scaffold beneath skin.
When it atrophies, the skin loses its internal support—independent of fat volume. - The combined loss is non-linear.
Fat loss + muscle loss together produce more visible aging
than either factor alone would predict.
Filling the fat back in addresses only half the equation.
The scaffold itself has been compromised.
The 2026 Paradigm Shift: From “Replenish” to “Protect and Strengthen”
The SCALE 2026 findings are accelerating a strategic shift
already underway in aesthetic medicine globally.
The old and new frameworks look like this:
1. Patient loses weight on GLP-1.
2. Face hollows and sags.
3. Inject hyaluronic acid or fat to restore volume.
4. Consider surgical lift if laxity is severe.
Before starting GLP-1: Establish baseline body composition; begin muscle-preservation habits.
During treatment: Use biostimulators (e.g., Sculptra, Radiesse) to maintain collagen production.
After weight stabilizes: Assess fat vs. muscle loss; design targeted volume restoration.
Throughout: Integrate EMS devices and resistance training to minimize lean mass depletion.
Three Evidence-Informed Strategies Emerging in 2026
Industry guidance (IAPAM, April–May 2026) recommends waiting until weight has been stable for several months
before pursuing significant volume restoration.
Treating a moving target produces inconsistent results and often requires costly revision.
Among survey respondents who owned neuromuscular stimulation (EMS) devices,
approximately half reported already incorporating EMS treatments into their GLP-1 patient protocols.
The goal: maintain the muscular scaffold while fat loss is occurring—
not just restore volume after the damage is done.
SCALE 2026 highlighted the importance of incorporating body composition assessment
into aesthetic consultations for GLP-1 patients.
Recommended protein intake during active weight loss: approximately 1.2–1.6g per kg of body weight per day.
Resistance training 2–3x per week is increasingly discussed as a standard co-prescription.
What This Means for GLP-1 Patients Globally
A critical clarification first:
“Ozempic Face” is not a direct side effect of GLP-1 drugs.
It is a consequence of rapid weight loss itself—
the same phenomenon seen after bariatric surgery or aggressive dieting.
GLP-1 medications, when prescribed through legitimate medical channels
with appropriate monitoring of weight loss rate, can minimize these effects.
The SCALE 2026 data reframes the clinical conversation in three important ways:
- Diagnosis before treatment:
Is the aging driven by fat loss, muscle loss, collagen depletion, or all three?
The answer determines the optimal intervention—and they are not interchangeable. - Prevention over correction:
Starting aesthetic planning before GLP-1 therapy begins
is more effective—and more cost-efficient—than correcting damage after the fact. - Integrated care models:
The prescribing physician and the aesthetic clinician need to communicate.
Siloed care produces suboptimal outcomes for patients navigating both weight loss and appearance goals.
The era of answering “I look older” with “let’s just fill it” is ending.
What SCALE 2026 demands is a more precise diagnostic question:
Why did this face age?
Was it fat? Muscle? Collagen? Skin quality?
Each answer points to a different solution—
and conflating them leads to treatments that look right on paper
but disappoint in the mirror.
Weight loss and aesthetic preservation are not competing goals.
They should be designed together, from the start—
before the first dose, not after the first complaint.
That integrated thinking is what NERO exists to advance.
Summary
- The SCALE Music City 2026 survey (406 healthcare professionals, May 2026) found that 91% believe lean muscle loss moderately or significantly contributes to skin laxity after GLP-1 weight loss;
90% said the same for overall facial aging.
This is a clinician perception survey—not a causal study—but it signals a meaningful shift in clinical thinking. - GLP-1 drugs reduce lean body mass alongside fat through aggressive caloric restriction.
The SEMALEAN study (semaglutide 2.4mg, n=106) documented approximately 3 kg lean mass loss in the first 7 months.
Facial musculature loss compounds the hollowing caused by fat pad depletion. - The 2026 approach moves from “replenish” to “protect and strengthen”:
weight stabilization before major procedures, EMS integration during treatment,
and protein/resistance training as co-prescriptions are becoming global standards. - For anyone using or considering GLP-1 therapy:
the most important shift is proactive aesthetic planning before treatment begins—
not reactive correction after aging becomes visible.
Coordinated care between prescribing and aesthetic clinicians is the emerging best practice.
Frequently Asked Questions
A moving baseline makes outcomes unpredictable and often requires costly revision.
However, biostimulators (such as Sculptra or Radiesse) aimed at maintaining collagen production—rather than adding volume—are discussed as a reasonable option during the active phase.
Individual consultation with your treating physician is essential.
Strategies discussed in the literature include:
adequate protein intake (approximately 1.2–1.6g per kg of body weight per day),
consistent resistance training (2–3 sessions per week),
and EMS device protocols where clinically appropriate.
Note: definitive evidence that any single intervention fully prevents lean mass loss during GLP-1 therapy remains limited.
Consult your physician for a personalized plan.
Once stable, a qualified aesthetic physician should assess the specific cause of your facial aging:
fat pad loss, lean muscle depletion, collagen reduction, or skin quality changes—
because each requires a different intervention.
Hyaluronic acid fillers, biostimulators, surgical lifting, and EMS-based muscle restoration
are all discussed in the 2026 literature as part of a staged, individualized protocol.
Source: Franco J et al. SCALE Music City 2026; Medscape July 22, 2026; JCAD 2026;19(7):16-22
Sources:
1. Franco J et al. “Survey of Aesthetic Concerns and Treatment Trends Associated With Loss of Lean Muscle Mass Following GLP-1-Associated Weight Loss.” SCALE Music City, May 13–17, 2026. EMJ Reviews. May 18, 2026.
2. Bommareddy K, Fabi S, Muniz M. “Aesthetic Considerations for Preventing and Managing GLP-1 Receptor Agonist–Related Facial Aging.” J Clin Aesthet Dermatol. 2026;19(7):16-22.
3. GLP-1 Drugs: Is Ozempic Face Changing Aesthetic Care? Medscape. July 22, 2026.
4. IAPAM. “GLP-1 Aesthetic Patients: A Clinical and Business Framework.” April–May 2026.
5. SEMALEAN Study. Semaglutide 2.4mg body composition findings. 2025–2026.
